Your search returned one study. (Get alerts for new studies):
- Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
Conditions: NHL - Lymphoma, Non-Hodgkin - Lymphoma, B-Cell - Lymphoma, Follicular - Lymphoma, Intermediate-Grade - Lymphoma, Large-Cell - Lymphoma, Low-Grade - Lymphoma, Mixed-Cell - Lymphoma, Small-Cell - Leukemia, Lymphocytic, Chronic - Leukemia, B-Cell, Chronic - 4 Locations available
|